Identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer

Abstract Background Patients with high‐intermediate risk endometrial cancer (H‐IR EMCA) have an elevated risk of recurrence compared to low‐risk counterparts. Many H‐IR EMCA patients are treated with radiation or chemotherapy, but their overall survival is not significantly impacted by treatment. Th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rebecca C. Arend, Carly B. Scalise, Jhalak Dholakia, Maahum Z. Kamal, Haley B. Thigpen, David Crossman, Warner K. Huh, Charles A. Leath III
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	biomarker endometrial cancer high‐intermediate risk mutations recurrence survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/88d7d8534aaa441ab511558f98f4d091
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:88d7d8534aaa441ab511558f98f4d091
record_format	dspace
spelling	oai:doaj.org-article:88d7d8534aaa441ab511558f98f4d0912021-11-22T09:08:48ZIdentifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer2045-763410.1002/cam4.4247https://doaj.org/article/88d7d8534aaa441ab511558f98f4d0912021-11-01T00:00:00Zhttps://doi.org/10.1002/cam4.4247https://doaj.org/toc/2045-7634Abstract Background Patients with high‐intermediate risk endometrial cancer (H‐IR EMCA) have an elevated risk of recurrence compared to low‐risk counterparts. Many H‐IR EMCA patients are treated with radiation or chemotherapy, but their overall survival is not significantly impacted by treatment. The objective of this study was to compare molecular profiles of H‐IR EMCA patients with disease recurrence to those without to identify characteristics that could better predict patient outcomes. Methods Tissue was acquired from H‐IR EMCA patients with disease recurrence (n=15) and without disease recurrence (n=15) who had not received adjuvant therapy and performed DNA and RNA analyses. Results In recurrent population, 5 patients had matchingrecurrent and initial tumor tissues. Of note, 5/7 (71%) African Americanpatients had disease recurrence compared to 10/23 (43%) White patients. Inaddition, several new mutations were found in individual patient’s recurrentcompared to initial tumors. Conclusions Currently the treatment ofendometrial cancer is rapidly changing with molecular profiling becoming partof the standard of care. Additionally, it and is being incorporated intoclinical trials in this group of patients. The specific gene mutations and RNAexpression signatures that were observed in our small cohort need to bevalidated in larger cohorts to determine their impact.Rebecca C. ArendCarly B. ScaliseJhalak DholakiaMaahum Z. KamalHaley B. ThigpenDavid CrossmanWarner K. HuhCharles A. Leath IIIWileyarticlebiomarkerendometrial cancerhigh‐intermediate riskmutationsrecurrencesurvivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 22, Pp 8238-8250 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarker endometrial cancer high‐intermediate risk mutations recurrence survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	biomarker endometrial cancer high‐intermediate risk mutations recurrence survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Rebecca C. Arend Carly B. Scalise Jhalak Dholakia Maahum Z. Kamal Haley B. Thigpen David Crossman Warner K. Huh Charles A. Leath III Identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer
description	Abstract Background Patients with high‐intermediate risk endometrial cancer (H‐IR EMCA) have an elevated risk of recurrence compared to low‐risk counterparts. Many H‐IR EMCA patients are treated with radiation or chemotherapy, but their overall survival is not significantly impacted by treatment. The objective of this study was to compare molecular profiles of H‐IR EMCA patients with disease recurrence to those without to identify characteristics that could better predict patient outcomes. Methods Tissue was acquired from H‐IR EMCA patients with disease recurrence (n=15) and without disease recurrence (n=15) who had not received adjuvant therapy and performed DNA and RNA analyses. Results In recurrent population, 5 patients had matchingrecurrent and initial tumor tissues. Of note, 5/7 (71%) African Americanpatients had disease recurrence compared to 10/23 (43%) White patients. Inaddition, several new mutations were found in individual patient’s recurrentcompared to initial tumors. Conclusions Currently the treatment ofendometrial cancer is rapidly changing with molecular profiling becoming partof the standard of care. Additionally, it and is being incorporated intoclinical trials in this group of patients. The specific gene mutations and RNAexpression signatures that were observed in our small cohort need to bevalidated in larger cohorts to determine their impact.
format	article
author	Rebecca C. Arend Carly B. Scalise Jhalak Dholakia Maahum Z. Kamal Haley B. Thigpen David Crossman Warner K. Huh Charles A. Leath III
author_facet	Rebecca C. Arend Carly B. Scalise Jhalak Dholakia Maahum Z. Kamal Haley B. Thigpen David Crossman Warner K. Huh Charles A. Leath III
author_sort	Rebecca C. Arend
title	Identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer
title_short	Identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer
title_full	Identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer
title_fullStr	Identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer
title_full_unstemmed	Identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer
title_sort	identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/88d7d8534aaa441ab511558f98f4d091
work_keys_str_mv	AT rebeccacarend identifyingamolecularprofiletopredicttheriskofrecurrenceinhighintermediateriskendometrialcancer AT carlybscalise identifyingamolecularprofiletopredicttheriskofrecurrenceinhighintermediateriskendometrialcancer AT jhalakdholakia identifyingamolecularprofiletopredicttheriskofrecurrenceinhighintermediateriskendometrialcancer AT maahumzkamal identifyingamolecularprofiletopredicttheriskofrecurrenceinhighintermediateriskendometrialcancer AT haleybthigpen identifyingamolecularprofiletopredicttheriskofrecurrenceinhighintermediateriskendometrialcancer AT davidcrossman identifyingamolecularprofiletopredicttheriskofrecurrenceinhighintermediateriskendometrialcancer AT warnerkhuh identifyingamolecularprofiletopredicttheriskofrecurrenceinhighintermediateriskendometrialcancer AT charlesaleathiii identifyingamolecularprofiletopredicttheriskofrecurrenceinhighintermediateriskendometrialcancer
_version_	1718417807902769152

Identifying a molecular profile to predict the risk of recurrence in high‐intermediate risk endometrial cancer

Ejemplares similares